U.S. overdose deaths decline in 2025 amid rising state-specific spikes and new drug threats

U.S. overdose deaths dropped about 14% in 2025 to roughly 70,000, with most states declining but Arizona, Colorado, and New Mexico seeing at least 10% increases, and a forensic lab identifying 27 new drugs in 2025 and 23 in the first five months of 2026.

Claim 1: In 2025, approximately 70,000 Americans died of drug overdoses, about 14% fewer than in 2024.

Evidence: Preliminary government data from the CDC recorded about 80,391 overdose deaths in 2024; a 14% reduction yields roughly 70,000 deaths, matching the figure reported by the Associated Press for 2025.

Verdict: True.

Analysis: The decline comes from death‑certificate surveillance, a cohort‑type monitoring system, not an experimental trial. While the trend correlates with expanded naloxone access and treatment funding, the data do not establish causation. Practically, the drop suggests recent public‑health measures may be saving lives, but continued monitoring is needed to confirm whether the trend will persist.

Claim 2: In 2025, overdose deaths decreased in most states but increased by at least 10% in Arizona, Colorado, and New Mexico.

Evidence: Preliminary CDC data cited by the AP indicate that the vast majority of states recorded lower death totals, with Arizona, Colorado, and New Mexico each showing jumps of 10% or more.

Verdict: True.

Analysis: These state‑level changes derive from the same provisional surveillance cohort. The pattern does not prove that state policies caused the rises; other factors such as shifting drug mixtures (e.g., fentanyl‑methamphetamine combinations) may be involved. Residents in those states should watch local emergency‑room reports and the availability of harm‑reduction services.

Claim 3: In 2025, the Center for Forensic Science Research and Education identified 27 new drugs, and in the first five months of 2026 it identified 23 new drugs.

Evidence: The lab’s director told the AP that the team detected 27 novel substances throughout 2025 and already 23 in the first five months of 2026.

Verdict: True.

Analysis: The lab operates as part of a CDC‑funded early‑warning system, systematically screening biological samples—a descriptive surveillance activity. The increase in detections reflects both evolving illicit chemistry and improved analytical capacity, not necessarily a surge in use. Health professionals should stay alert to alerts about potent synthetics such as cychlorphine, which can be mixed unknowingly into other drugs.

What to watch next: Federal policy shifts affecting naloxone and test‑strip funding, the emergence of stronger synthetic opioids, and whether the state‑specific spikes persist or reverse in the coming months.